Drug resistance in cancer remains a major challenge in oncology, impeding the effectiveness of various treatment modalities. The nuclear factor-kappa B (NF-κB) signaling pathway has emerged as a critical player in the development of drug resistance in cancer cells. This comprehensive review explores the intricate relationship between NF-κB and drug resistance in cancer. We delve into the molecular mechanisms through which NF-κB activation contributes to resistance against chemotherapeutic agents, targeted therapies, and immunotherapies. Additionally, we discuss potential strategies to overcome this resistance by targeting NF-κB signaling, such as small molecule inhibitors and combination therapies. Understanding the multifaceted interactions between NF-κB and drug resistance is crucial for the development of more effective cancer treatment strategies. By dissecting the complex signaling network of NF-κB, we hope to shed light on novel therapeutic approaches that can enhance treatment outcomes, ultimately improving the prognosis for cancer patients. This review aims to provide a comprehensive overview of the current state of knowledge on NF-κB and its role in drug resistance, offering insights that may guide future research and therapeutic interventions in the fight against cancer.

中文翻译：

---

抑制 NF-κB 信号传导揭示了克服癌症耐药性的新策略

癌症的耐药性仍然是肿瘤学的一个主要挑战，阻碍了各种治疗方式的有效性。核因子-κB (NF-κB) 信号通路已成为癌细胞耐药性发展的关键参与者。这篇综合综述探讨了 NF-κB 与癌症耐药性之间的复杂关系。我们深入研究 NF-κB 激活导致化疗药物、靶向治疗和免疫治疗耐药的分子机制。此外，我们还讨论了通过靶向 NF-κB 信号传导克服这种耐药性的潜在策略，例如小分子抑制剂和联合疗法。了解 NF-κB 与耐药性之间的多方面相互作用对于制定更有效的癌症治疗策略至关重要。通过剖析 NF-κB 的复杂信号网络，我们希望揭示能够增强治疗效果的新治疗方法，最终改善癌症患者的预后。本综述旨在全面概述 NF-κB 的现状及其在耐药性中的作用，提供可能指导未来抗癌研究和治疗干预的见解。